Renal denervation in treatment-resistant hypertension: A reappraisal

Current Opinion in Pharmacology

Volumn 21, Issue , 2015, Pages 48-52

  Persu, Alexandre ^a,b   Jin, Yu ^c   Fadl Elmula, Fadl Elmula M ^d   Renkin, Jean ^a,b   Høieggen, Aud ^d   Kjeldsen, Sverre E ^d   Staessen, Jan A ^c,e  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^e MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIURETIC AGENT;

CATHETER ABLATION; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); DEVICE SAFETY; HUMAN; HYPERTENSION; KIDNEY ARTERY STENOSIS; KIDNEY DENERVATION; KIDNEY DENERVATION SYSTEM; OUTCOME ASSESSMENT; REVIEW; SYSTOLIC BLOOD PRESSURE; DRUG RESISTANCE; INNERVATION; KIDNEY; PATHOPHYSIOLOGY; SYMPATHECTOMY;

DRUG RESISTANCE; HUMANS; HYPERTENSION; KIDNEY; SYMPATHECTOMY;

EID: 84921367309     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2014.12.013     Document Type: Review

References (40)

1. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M: Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009, 373:1275-1281.
2. Symplicity HTN-2 Investigators, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M: Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010, 376:1903-1909.
3. Symplicity HTN-1 Investigators: Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011, 57:911-917.
4. Demaria AN: Reflections on renal denervation. J Am Coll Cardiol 2014, 63:1452-1453.
5. Fadl Elmula FE, Hoffmann P, Larstorp AC, Fossum E, Brekke M, Kjeldsen SE, Gjønnæss E, Hjørnholm U, Kjaer VN, Rostrup M, Os I, Stenehjem A, Høieggen A: Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension 2014, 63:991-999.
6. Schlaich MP, Krum H, Esler MD: New therapeutic approaches to resistant hypertension. Curr Hypertens Rep 2010, 12:296-302.
7. Persu A, Renkin J, Thijs L, Staessen JA: Renal denervation: ultima ratio or standard in treatment-resistant hypertension. Hypertension 2012, 60:596-606.
8. Azizi M, Steichen O, Frank M, Bobrie G, Plouin PF, Sapoval M: Catheter-based radiofrequency renal-nerve ablation in patients with resistant hypertension. Eur J Vasc Endovasc Surg 2012, 43:293-299.
9. Howard JP, Nowbar AN, Francis DP: Size of blood pressure reduction from renal denervation: insights from meta-analysis of antihypertensive drug trials of 4,121 patients with focus on trial design: the CONVERGE report. Heart 2013, 99:1579-1587.
10. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M et al.: SYMPLICITY HTN-3 Investigators: A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014, 370:1393-1401.
11. Lüscher TF, Mahfoud F: Renal nerve ablation after SYMPLICITY HTN-3: confused at the higher level? Eur Heart J 2014, 35:1706-1711.
12. Schmieder RE: Hypertension: how should data from SYMPLICITY HTN-3 be interpreted? Nat Rev Cardiol 2014, 11:375-376.
13. Esler M: Illusions of truths in the Symplicity HTN-3 trial: generic design strengths but neuroscience failings. J Am Soc Hypertens 2014, 8:593-598.
14. Kandzari DE, Bhatt DL, Brar S, Devireddy CM, Esler M, Fahy M, Flack JM, Katzen BT, Lea J, Lee DP et al. : Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J 2014. (Epub ahead of print).
15. Myers MG, Wijeysundera HC: Renal nerve denervation - a hypertension bubble? J Clin Hypertens (Greenwich) 2014, 16:472-474.
16. Rosa J, Widimský P, Toušek P, Petrák O, Curila K, Waldauf P, Bednář F, Zelinka T, Holaj R, Strauch B et al.: Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the PRAGUE-15 study. Hypertension 2014. (Epub ahead of print).
17. Azizi M, Monge M, Pereira H, Sapoval M, on behalf of DENER-HTN investigators: The French DENER-HTN Trial: renal denervation + standardized antihypertensive treatment vs. standardized antihypertensive treatment alone in patients with resistant hypertension. J Hypertens 2014, 32(e-Suppl. 1):e89 http://www.hypertension2014.org/wordpress/wp-content/uploads/2014/06/ESH-ISH-2014-Abstract-Book-Oral.pdf.
18. http://www.tctmd.com/show.aspx?id=126422 (accessed 02.10.14)
19. Persu A, Jin Y, Azizi M, Baelen M, Völz S, Elvan A, Severino F, Rosa J, Adiyaman A, Fadl Elmula FE et al.: European Network Coordinating research on Renal Denervation (ENCOReD) Blood pressure changes after renal denervation at 10 European expert centers. J Hum Hypertens 2014, 28:150-156.
20. Persu A, Sapoval M, Azizi M, Monge M, Danse E, Hammer F, Renkin J: Renal artery stenosis following renal denervation: a matter of concern. J Hypertens 2014, 32 :2101-2105.
21. Bhamra-Ariza P, Rao S, Muller DW: Renal artery stenosis following renal percutaneous denervation. Catheter Cardiovasc Interv 2014, 84:1180-1183.
22. Cordeanu ME, Gaertner S, Bronner F, Jahn C, Prinz E, Hannedouche T, Stephan D: Neointimal thickening resulting in artery stenosis following renal sympathetic denervation. Int J Cardiol 2014, 177:e117-e119.
23. Geisler BP, Egan BM, Cohen JT, Garner AM, Akehurst RL, Esler MD, Pietzsch JB: Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension. J Am Coll Cardiol 2012, 60:1271-1277.
24. Dorenkamp M, Bonaventura K, Leber AW, Boldt J, Sohns C, Boldt LH, Haverkamp W, Frei U, Roser M: Potential lifetime cost-effectiveness of catheter-based renal sympathetic denervation in patients with resistant hypertension. Eur Heart J 2013, 34 :451-461.
25. Gladwell D, Henry T, Cook M, Akehurst R: Cost effectiveness of renal denervation therapy for the treatment of resistant hypertension in the UK. Appl Health Econ Health Policy 2014. (Epub ahead of print).
26. Bhatt DL: What does the future hold for renal denervation? Eur Heart J 2014, 35:1695-1696.
27. Kjeldsen SE, Fadl Elmula FE, Persu A, Jin Y, Staessen JA: Renal sympathetic denervation in the aftermath of Symplicity HTN-3. Blood Press 2014, 23:256-261.
28. Böhm M, Mahfoud F: SYMPLICITY HTN-3 trial: what is it and what does it mean? Eur Heart J 2014, 35:1697-1698.
29. Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J, de Leeuw PW, Sica DA: Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled Rheos pivotal trial. J Am Coll Cardiol 2011, 58:765-773.
30. Burchell AE, Lobo MD, Sulke N, Sobotka PA, Paton JF: Arteriovenous anastomosis: is this the way to control hypertension? Hypertension 2014, 64:6-12.
31. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D et al.: Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008, 51:1403-1419.
32. Kjeldsen SE, Julius S, Dahlöf B, Weber MA: Physician (investigator) inertia in apparent treatment-resistant hypertension - Insights from large randomized clinical trials. Blood Press 2014, 27:1-6.
33. Persell SD: Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 2011, 57:1076-1080.
34. Weitzman D, Chodick G, Shalev V, Grossman C, Grossman E: Prevalence and factors associated with resistant hypertension in a large health maintenance organization in Israel. Hypertension 2014, 64:501-507.
35. Hayek SS, Abdou MH, Demoss BD, Legaspi JM, Veledar E, Deka A, Krishnan SK, Wilmot KA, Patel AD, Kumar VR, Devireddy CM: Prevalence of resistant hypertension and eligibility for catheter-based renal denervation in hypertensive outpatients. Am J Hypertens 2013, 26:1452-1458.
36. Ceral J, Habrdova V, Vorisek V, Bima M, Pelouch R, Solar M: Difficult-to-control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy. Hypertens Res 2011, 34:87-90.
37. Jung O, Gechter JL, Wunder C, Paulke A, Bartel C, Geiger H, Toennes SW: Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens 2013, 31:766-774.
38. Rosa J, Zelinka T, Petrák O, Strauch B, Somlóová Z, Indra T, Holaj R, Curila K, Toušek P, Senitko M, Widimský P, Widimský J Jr: Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically? J Hum Hypertens 2014. (Epub ahead of print).
39. Tomaszewski M, White C, Patel P, Masca N, Damani R, Hepworth J, Samani NJ, Gupta P, Madira W, Stanley A, Williams B: High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) urine analysis. Heart 2014, 100:855-861.
40. Persu A, Jin Y, Baelen M, Vink E, Verloop WL, Schmidt B, Blicher MK, Severino F, Wuerzner G, Taylor A et al.: European Network Coordinating research on Renal Denervation Consortium: Eligibility for renal denervation: experience at 11 European expert centers. Hypertension 2014, 63:1319-1325.